Ming Jian and Zhang Qingfu contributed equally to this work as co-first authors.
Anti-lymphangiogenesis effects of a specific anti-interleukin 7 receptor antibody in lung cancer model in vivo
Article first published online: 24 SEP 2013
© 2013 Wiley Periodicals, Inc.
How to Cite
Jian, M., Qingfu, Z., Yanduo, J., Guocheng, J. and Xueshan, Q. (2013), Anti-lymphangiogenesis effects of a specific anti-interleukin 7 receptor antibody in lung cancer model in vivo. Mol. Carcinog.. doi: 10.1002/mc.22082
Conflict of interest: The authors declare that they have no competing interests.
- Article first published online: 24 SEP 2013
- Manuscript Accepted: 7 AUG 2013
- Manuscript Revised: 19 JUL 2013
- Manuscript Received: 2 APR 2013
- Science Foundation of China. Grant Number: 30972967
- Specialized Research Fund for the Doctoral Program of Higher Education. Grant Number: 20092104110018
- interleukin 7;
- interleukin 7 receptor;
- lung cancer;
- in vivo;
Interleukin 7 (IL-7) is known to promote lymphangiogenesis. To study the relationship between IL-7 and the lymphangiogenesis in lung cancer cells xenograft tumors, we investigated how IL-7 regulates lymphangiogenesis by Quantitative real-time reverse transcriptase–polymerase chain reaction, Western blot, co-immunoprecipitation, chromatin immunoprecipitation, and immunohistochemistry methods. We found that, in lung cancer cells xenograft tumors IL-7/IL-7 receptor (IL-7R) increase the expression of VEGF-D and lymphangiogenesis, induce c-Fos and c-Jun heterodimer formation, and enhance c-Fos/c-Jun DNA binding activity to regulate VEGF-D. Taken together, our results provided evidence that IL-7/IL-7R induce VEGF-D upregulation and promote lymphangiogenesis via c-Fos/c-Jun pathway in lung cancer. © 2013 Wiley Periodicals, Inc.